Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Prepaid Assets (2016 - 2026)

Akebia Therapeutics has reported Prepaid Assets over the past 11 years, most recently at $3.8 million for Q4 2025.

  • Quarterly Prepaid Assets fell 48.49% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, down 48.49% year-over-year, with the annual reading at $3.8 million for FY2025, 48.49% down from the prior year.
  • Prepaid Assets was $3.8 million for Q4 2025 at Akebia Therapeutics, down from $5.3 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $42.1 million in Q2 2022 and troughed at $3.8 million in Q4 2025.
  • The 5-year median for Prepaid Assets is $18.9 million (2024), against an average of $18.9 million.
  • Year-over-year, Prepaid Assets soared 337.11% in 2021 and then plummeted 71.82% in 2024.
  • A 5-year view of Prepaid Assets shows it stood at $33.1 million in 2021, then plummeted by 47.95% to $17.2 million in 2022, then rose by 17.36% to $20.2 million in 2023, then crashed by 63.83% to $7.3 million in 2024, then tumbled by 48.49% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Prepaid Assets are $3.8 million (Q4 2025), $5.3 million (Q3 2025), and $7.8 million (Q2 2025).